Search concepts
|
Selected filters
|
- 500 - 550 out of 6,894 results
- Export search results
Search results
-
Antibiotic resistance: combining microscopy, microfluidics and genomics to target bacterial DNA repair pathways
Robinson, A., Paulsen, I. & Jin, D.
1/01/19 → 31/12/21
Project: Other
-
Antibiotic resistance and the ecological effects of selective decontamination of the digestive tract in Intensive Care Units
Paulsen, I., Iredell, J., Partridge, S., Darling, A. & Seppelt, I.
1/01/17 → …
Project: Research
-
Antimicrobial compounds from the model marsupial, the Tammar wallaby (Macropus eugenii )
Ambatipudi, S.
1/07/06 → 30/06/08
Project: Research
-
Ant inspired rules for self-assembly in swarm robotics and complex systems
1/05/19 → 30/04/22
Project: Research
-
-
AntiPort - Educating the Public on the risks and prevention of Mobile Number Porting Scams
Trueck, S., Selby, J., Doche, C. & Boyd, M.
1/02/19 → 31/12/20
Project: Research
-
Anywhere Working (Telework) and Telehealth Delivery: Productivity, Wellbeing and Service Quality
Blount, Y., Markey, R. & Gloet, M.
1/01/14 → 31/12/15
Project: Research
-
-
APECS determination of Auger parameters of C and Si
Thurgate, S. & van Rissen, G.
23/04/07 → 25/04/07
Project: Research
-
-
A Personalized Social Network Based Location Search and Recommender System
Yang, J., Orgun, M., Wang, Y., Air, M., Eichhorn, B. & Rej, T.
1/05/13 → …
Project: Research
-
A Pharmacological Targeting Approach Implementing Albumin as a Carrier of a Novel Chemotherapeutic
Lovejoy, D., Kalinowski, D., Rahmanto, Y. & Ponka, P.
1/01/13 → 31/12/15
Project: Research
-
ADG116-1003: A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients with Advanced/Metastatic Solid Tumors
Park, J., Chapman, N. & Sabanathan, D.
14/09/20 → 27/08/25
Project: Research
-
Y-biologics: A Phase 1, Open-Label, Multicenter, Single Arm, Dose-Escalation/Dose-Expansion Study of YBL-006 in Patients with Advanced Solid Tumors
Sabanathan, D., Park, J., Gurney, H., Chapman, N. & Rai, M.
1/06/20 → 30/04/23
Project: Research
-
AB928CSP0002: A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies
Sabanathan, D., Kefford, R., Cunningham, J. & Butala, R.
6/12/18 → 5/12/23
Project: Other
-
A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma
Sabanathan, D., Chapman, N., Butala, R. & Gurney, H.
16/05/19 → 15/05/24
Project: Other
-
A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma
Sabanathan, D., Chapman, N., Butala, R. & Gurney, H.
16/05/19 → 15/05/24
Project: Other
-
A Phase 1B, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination with Rucaparib in patients with Advanced Breast, Ovarian, or Prostate Cancer
Gurney, H., Chapman, N. & Butala, R.
5/08/19 → 26/06/24
Project: Other
-
A Phase 1B/2 study to evaluate safety and anti-tumour activity of AVELUMAB in combination with POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) inhibitor TALAZOPARIB in patients with locally advance or metastatic solid tumours
Sabanathan, D., Kefford, R., Butala, R. & Cunningham, J.
19/07/18 → 21/06/23
Project: Research
-
C0541001: A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF 06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE AND NEGATIVEe SOLID TUMORS
Sabanathan, D. & Chapman, N.
21/09/20 → 31/05/25
Project: Research
-
Harbour Biomed 4003.1: A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors
Gurney, H., Chapman, N., Butala, R., Parshionikar, A. & Rajasekharan Nair, A.
30/09/19 → 30/09/24
Project: Other
-
MISC_Covance Chiltern: A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients with Advanced Solid Tumors
Gurney, H., Butala, R. & Cunningham, J.
16/07/18 → 15/07/23
Project: Other
-
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
Gurney, H., Cunningham, J. & Butala, R.
1/12/18 → 30/11/23
Project: Other
-
GALAXI: A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
Leong, R., Butala, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
30/09/19 → 7/05/24
Project: Research
-
VEGA: A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Leong, R., Butala, R. & Chapman, N.
24/09/19 → 11/07/24
Project: Other
-
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Gurney, H., Cunningham, J. & Butala, R.
17/10/18 → 4/09/23
Project: Other
-
A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1
Kefford, R., Butala, R. & Cunningham, J.
12/03/19 → 25/11/23
Project: Other
-
ADVANCE-outcomes: A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH: APD811-301
Brown, M., Butala, R. & Chapman, N.
17/10/19 → 30/06/22
Project: Research
-
LEAP-011: A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression: Protocol MK7902-011-00
Zhang, A., Butala, R. & Chapman, N.
13/09/19 → 6/06/24
Project: Research
-
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer.
Zhang, A., Chapman, N. & Butala, R.
6/08/19 → 18/06/24
Project: Other
-
M14-533: A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis
Leong, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
17/12/19 → 26/09/24
Project: Research
-
ADVANCE-outcomes 303: A phase 3 open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in subjects with World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH): ADP811-303
Brown, M., Butala, R. & Chapman, N.
17/10/19 → 30/06/22
Project: Research
-
Checkmate 914: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Gurney, H., Chapman, N. & Zhang, A.
17/08/20 → 4/06/25
Project: Research
-
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Gurney, H., Chapman, N. & Butala, R.
28/02/19 → 27/02/24
Project: Other
-
KEYNOTE-905: A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscle-invasive Bladder Cancer (MK3475-905)
Zhang, A., Chapman, N. & Parshionikar, A.
13/09/19 → 6/06/24
Project: Other
-
CN1-101: A phase I, open label, multi-center,dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma
Park, J., Chapman, N., Gurney, H. & Sabanathan, D.
3/08/20 → 30/06/25
Project: Research
-
CS1001/Regorafenib-101: A phase Ib/II multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors
Park, J., Gurney, H., Parshionikar, A., Chapman, N. & Rai, M.
Project: Research
-
IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer
Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
22/11/19 → 30/09/24
Project: Other
-
IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer
Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
22/11/19 → 30/09/24
Project: Other
-
IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer
Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
22/11/19 → 30/09/24
Project: Other
-
IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer
Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
22/11/19 → 30/09/24
Project: Other
-
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1 Antibody) in combination with adjuvant Anthracycline/Taxane-based Chemotherapy versus Chemotherapy Alone in patients with operable Triple-Negative Breast Cancer
Sabanathan, D., Kefford, R., Chapman, N. & Butala, R.
5/08/19 → 24/10/23
Project: Other
-
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)
Sabanathan, D., Kefford, R. & Cunningham, J.
21/03/19 → 20/03/24
Project: Other
-
IMbrave050: A phase III, multicentre, randomized, open-label study of atezolizumab (anti-PD-L1 antibody) plus bevacizumab plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablationR SURGICAL RESECTION OR ABLATION
Poursoltan, P., Chapman, N. & Parshionikar, A.
11/12/19 → 30/09/24
Project: Other